Ibrahim Yildiz1, Meltem Ekenel2, Tulay Akman3, Muharrem Kocar4, Mükremin Uysal5, Metin Kanitez6, Umut Varol7, Ibrahim Vedat Bayoglu7, Deniz Tural8, Mehmet Ali Kaplan9, Nilufer Avci10, Zeki Sürmeli11, İsa Dede12, Arife Ulaş13, Ozan Yazici14, Mert Basaran2. 1. Departments of Medical Oncology at: Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey dr_ibrahim2000@yahoo.com. 2. Departments of Medical Oncology at: Institute of Oncology, Istanbul University, Istanbul, Turkey. 3. Departments of Medical Oncology at: Izmir Tepecik Training and Research Hospital, Izmir, Turkey. 4. Departments of Medical Oncology at: Sanliurfa Education and Research Hospital, Sanliurfa, Turkey. 5. Departments of Medical Oncology at: Afyon Kocatepe University, Afyonkarahisar, Turkey. 6. Departments of Medical Oncology at: Marmara University Hospital, Istanbul, Turkey. 7. Departments of Medical Oncology at: Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey. 8. Departments of Medical Oncology at: Cerrahpasa Faculty of Medicine, Istanbul University, Istanbul, Turkey. 9. Departments of Medical Oncology at: Dicle University, Diyarbakir, Turkey. 10. Departments of Medical Oncology at: Balikesir State Hospital, Balikesir, Turkey. 11. Departments of Medical Oncology at: Ege University, Tulay Aktas Oncology Hospital, Izmir, Turkey. 12. Departments of Medical Oncology at: Ankara University Medical Faculty, Ankara, Turkey. 13. Departments of Medical Oncology at: Ali Osman Sonmez Oncology Training and Research Hospital, Bursa, Turkey. 14. Departments of Medical Oncology at: Ankara Numune Education and Research Hospital, Ankara, Turkey.
Abstract
AIM: This study aimed to assess the clinical efficacy and toxicity of sunitinib, a targeted-agent, for non-clear cell renal cell carcinoma. PATIENTS AND METHODS: Sixty-three patients with complete clinical data from 13 oncology Centers were retrospectively evaluated. Outcomes analyzed were objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and adverse events. RESULTS: The median age of all patients, 38 men (60.3%) and 25 women (39.7%), was 63 years (range=25-82 years). Histological subtypes included 46 (88%) cases of papillary RCC, 10 of chromophobe, and 7 unclassified cases. Median treatment duration was seven months (range=2-86 months). At the time of this analysis, 52 patients had discontinued treatment, 33 of whom had died. Treatment discontinuation was due to disease progression in 43 patients, and toxicity in nine. Dose interruption was necessary in 22 (34.9%) patients, and dose reduction in 27 (42.9%). The objective response rate and disease control rate were 11.1% and 63.5%, respectively. The median PFS and OS were 7.6 months (95% confidence interval (CI)=5.5-9.7 months) and 22.0 months (95% CI=13.4-30.6 months), respectively, with 1-year rates of 64.7% and 33.7%, respectively. CONCLUSION: Clinical outcome of the metastatic non-clear cell RCC patients with sunitinib treatment seemed to be worse than the historical data of clear cell RCC patients, in terms of PFS, OS and objective response. New and more effective targeted-therapies and better understanding of the underlying molecular processes are necessary to improve survival outcome for these patients. Copyright
AIM: This study aimed to assess the clinical efficacy and toxicity of sunitinib, a targeted-agent, for non-clear cell renal cell carcinoma. PATIENTS AND METHODS: Sixty-three patients with complete clinical data from 13 oncology Centers were retrospectively evaluated. Outcomes analyzed were objective response rate (ORR), progression-free survival (PFS), overall survival (OS) and adverse events. RESULTS: The median age of all patients, 38 men (60.3%) and 25 women (39.7%), was 63 years (range=25-82 years). Histological subtypes included 46 (88%) cases of papillary RCC, 10 of chromophobe, and 7 unclassified cases. Median treatment duration was seven months (range=2-86 months). At the time of this analysis, 52 patients had discontinued treatment, 33 of whom had died. Treatment discontinuation was due to disease progression in 43 patients, and toxicity in nine. Dose interruption was necessary in 22 (34.9%) patients, and dose reduction in 27 (42.9%). The objective response rate and disease control rate were 11.1% and 63.5%, respectively. The median PFS and OS were 7.6 months (95% confidence interval (CI)=5.5-9.7 months) and 22.0 months (95% CI=13.4-30.6 months), respectively, with 1-year rates of 64.7% and 33.7%, respectively. CONCLUSION: Clinical outcome of the metastatic non-clear cell RCCpatients with sunitinib treatment seemed to be worse than the historical data of clear cell RCCpatients, in terms of PFS, OS and objective response. New and more effective targeted-therapies and better understanding of the underlying molecular processes are necessary to improve survival outcome for these patients. Copyright
Authors: Javier Puente; Xavier García Del Muro; Álvaro Pinto; Nuria Láinez; Emilio Esteban; José Ángel Arranz; Enrique Gallardo; María José Méndez; Pablo Maroto; Enrique Grande; Cristina Suárez Journal: Target Oncol Date: 2016-04 Impact factor: 4.493